CMT-3. CollaGenex
Fingleton, B.
Current Opinion in Investigational Drugs 4(12): 1460-1467
2003
ISSN/ISBN: 1472-4472 PMID: 14763133 Document Number: 553876
CMT-3 is an orally active matrix metalloprotease inhibitor, and one of a series of inhibitors of multiple proteases and cytokines, under development by CollaGenex. The compound is currently undergoing phase II trials for the potential treatment of cancer, in particular metastatic cancer and HIV-related Kaposi's sarcoma.